期刊文献+

奥曲肽和特利加压素单用或联用对肝硬化患者肝静脉压力梯度的影响 被引量:8

Individual and combined effects of octreotide and terlipressin on hepatic venous pressure gradient in cirrhotic patients
下载PDF
导出
摘要 目的分别观察奥曲肽和特利加压素单用及二者联合对肝静脉压力梯度(HVPG)的影响。方法收集2011年1月-2014年4月山东大学附属省立医院消化科住院的肝硬化并静脉曲张患者49例,将患者分成奥曲肽组(A组)、特利加压素组(B组)、联合用药组(C组)。A组:奥曲肽0.1 mg静推(给药时间1 min),继以25μg/h泵入,分别测给药前及给药后1、5、10和15 min时的HVPG;B组:特利加压素1 mg静推(2 min内完成),分别测给药前及给药后10、20和30 min时的HVPG;C组:首先给予奥曲肽,分别测奥曲肽给药前及给药后1、5、10和15 min的HVPG,继以联合特利加压素静推,分别测定联合特利加压素后10、20和30 min时的HVPG。采用t检验、方差分析和卡方检验对数据进行统计学分析。结果 A组奥曲肽给药后1.5、10和15 min HVPG显著下降(t值分别为13.173、5.364、3.894、4.160,P值均<0.001),但5、10和15 min之间差异无统计学意义(P值均>0.05)。B组特利加压素给药20 min后HVPG显著下降(t=4.062,P=0.002),20和30 min HVPG之间差异有统计学意义(t=4.022,P=0.002)。C组加用特利加压素20 min后HVPG进一步下降(t=4.926,P<0.001),20和30 min HVPG之间差异无统计学意义(t=1.733,P=0.101)。三组疗效差异有统计学意义,C组疗效明显大于A、B组(F=10.423,P<0.05)。结论奥曲肽能很快降低肝硬化门静脉高压患者的HVPG,但短期内有所回升且趋于稳定。特利加压素单独应用亦能降低HVPG,起效时间比奥曲肽慢。奥曲肽加用特利加压素后可进一步降低HVPG,效果优于单独用药。 Objective The administration of octreotide, as well as terlipressin, is a routine treatment for acute variceal bleeding in cirrhotic patients. This study aimed to evaluate the effects of octreotide, terlipressin, and their combination on hepatic venous pressure gradient (HVPG) in cirrhotic patients. Methods The study enrolled 49 cirrhotic patients with varicose veins who were hospitalized at the Depart- ment of Gastroenterology, Shandong Provincial Hospital Mfiliated to Shandong University during January 2011 to April 2014. The patients were divided into three groups: group A (octreotide alone) , group B (terlipressin alone) , and group C (the combination). Group A: Oct- reotide was administered via intravenous injection of 1.0 mg within 1 min followed by intravenous pumping at 25 μg/h, and HVPG was measured before drug administration and at 1, 5, 10, and 15 min after the start of octreotide injection. Group B : Terlipressin was adminis- tered by intravenous injection of 1 mg within 2 min, and I-IVPG was measured before drug administration and at 10, 20, and 30 min after the start of terlipressin injection. Group C : First, octreotide was administered and HVPG was measured as performed for group A ; then, terlip- ressin was given and HVPG was measured as performed for group B. Data were statistically analyzed using the t test, analysis of variance, and chi - square test. Results In group A, HVPG was significantly decreased at different time points after octreotide injection ( t = 13. 173, P 〈 0. 001 ; t = 5. 364, P 〈 0. 001 ; t = 3. 894, P= 0. 001 ; t = 4. 160, P 〈 0. 001 ) , but no significant differences were found between 5, 10, and 15 rain (all P 〉 0.05 ). In group B, HVPG was significantly decreased at 20 min after terlipressin injection (t = 4. 062, P = 0. 002 ) ,with significant difference between 20 and 30 rain ( t = 4. 022, P = 0. 002). In group C, HVPG was further decreased at 20 rain after terlip- ressin injection ( t = 4. 926, P 〈 0. 001 ), with n
出处 《临床肝胆病杂志》 CAS 2015年第2期214-218,共5页 Journal of Clinical Hepatology
关键词 肝硬化 奥曲肽 特利加压素 肝静脉 liver cirrhosis octreotide terlipressin hepatic veins
  • 相关文献

参考文献12

  • 1王吉耀.重视肝硬化患者门静脉压力的检测——从研究工具到临床应用[J].临床肝胆病杂志,2012,28(9):642-643. 被引量:4
  • 2GROSZMANN R J, GARCIA -TSAO G, BOSCH J, et al. Beta - blockers to prevent gastroesophageal varices in patients with cirrhosis[J]. N Engl J Med, 2005, 353(21 ) : 2254 -2261. 被引量:1
  • 3D' AMICO G, GARCIA - PAGAN JC, LUCA A, et al. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review[ J]. Gastroenterol- ogy, 2006, 131 (5) : 1624. 被引量:1
  • 4曹旬旬,陆伦根.肝静脉压力梯度在肝硬化门静脉高压症患者中的临床应用[J].临床肝胆病杂志,2013,29(9):715-718. 被引量:8
  • 5廖真防.不同剂量奥曲肽治疗食管胃静脉曲张破裂出血的疗效和安全性[J].当代医学,2012,18(32):37-38. 被引量:3
  • 6MEJIAS M, GARCIA -PRAS E, TIANI C, et al. The soma- tostatin analogue octreotide inhibits angiogenesis in the earli- est, but not in advanced, stages of portal hypertension in rats[J]. J Cell Mol Med, 2008, 12(5A) : 1690 -1699. 被引量:1
  • 7CHAN MM, CHAN MM, MENGSHOL JA, et al. Octreotide: a drug often used in the critical care setting but not well un- derstood[J]. Chest, 2013, 144(6) : 1937 -1945. 被引量:1
  • 8WANG J, WANG L, SONG G, et al. The mechanism through which octreotide inhibits hepatic stellate cell activity [J ]. Mol Med Rep, 2013, 7(5) : 1559 -1564. 被引量:1
  • 9VILLANUEVA C, PLANELLA M, ARACIL C, et al. Hemody- namic effects of terlipressin and high somatostatin dose dur-ing acute variceal bleeding in matostatin dose [ J ]. Am J nonresponders to the usual so- Gastroenterol, 2005, 100 ( 3 ) : 624 -630. 被引量:1
  • 10NARAHARA Y, KANAZAWA H, TAKI Y, et al. Effects of ter- lipressin on systemic, hepatic and renal hemodynamics in pa- tients with cirrhosis [ J ]. J Gastroenterol Hepatol, 2009, 24 (11) : 1791 -1797. 被引量:1

二级参考文献18

  • 1Jennifer Addley,Tony CK Tham,William Jonathan Cash.Use of portal pressure studies in the management of variceal haemorrhage[J].World Journal of Gastrointestinal Endoscopy,2012,4(7):281-289. 被引量:38
  • 2陈育建,高峰,李雪飞.国产生长抑素与善宁治疗食管-胃底静脉曲张破裂出血的对比研究[J].实用临床医学(江西),2006,7(6):44-45. 被引量:2
  • 3Groszmann R, Vorobioff JD. Measurement of portal pres- sure: When, How, and Why to do it[J]. Clin Liver Dis, 2006, (10) : 499 -512. 被引量:1
  • 4Triantos CK, Nikolopoulou V, Burroughs AK. Review article: the therapeutic and prognostic benefit of portal pressure re- duction in cirrhosis [ J ]. Aliment Pharmacol Ther, 2008, 28 (8) :943 -952. 被引量:1
  • 5Burroughs AK, Thalheimer U. Hepatic venous pressure gra- dient in 2010 . optimal measurement is key[ J ] . Hepatology, 2010, 51 (6) :1894 -1896. 被引量:1
  • 6Abraldes JG, Tarantinol, Turnes J, et al. Hemodynamic re- sponse to pharmacological treatment of portal hypertension and long -term prognosis of cirrhosis [ J ]. Hepatology, 2003, 37(4) :902 -908. 被引量:1
  • 7Ripoll C, Groszmann R, Garcia -Tsao G, et al. Hepatic ve- nous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis [ J ]. Gastroenterology, 2007, 133(2) : 481 -488. 被引量:1
  • 8Rockey DC, Friedman SL. Hepatic fibrosis and cirrhosis in BoyerTD, Manns MP, Sanyal AJ eds, Zakim & Boyer' s Hepatology 6th ELSEVER Philadelphia USA, 2012: 77. 被引量:1
  • 9Guadalupe Garcia - TsaoHepatic Venous Pressure Gradient, Biopsy or Both? In Roberto de Franchised. Portal Hyperten- sion V, 5th edition. Blackwell Publishing Ltd, 2011 :9 -17. 被引量:1
  • 10Kalambokis G, Manousou P, Samonakis D, et al. Clinical outcome of HCV - related graft cirrhosis and prognostic value of hepatic venous pressure gradient[ J]. Transpl Int, 2009, 22(2): 172 -181. 被引量:1

共引文献12

同被引文献71

引证文献8

二级引证文献48

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部